Activatable Water Soluble Probes Enhance Tumor Imaging by Responding to Dysregulated pH and Exhibiting High Tumor-to-liver Fluorescence Emission Contrast

Hu Xiong, Petra Kos, Yunfeng Yan, Kejin Zhou, Jason B. Miller, Sussana Elkassih, and Daniel J. Siegwart*

The University of Texas Southwestern Medical Center, Simmons Comprehensive Cancer Center, Department of Biochemistry, Dallas, Texas 75390, United States. *Correspondence should be addressed to daniel.siegwart@utsouthwestern.edu

Supporting Information

Contents

1. General information	S2
2. Supplemental Tables and Figures	S3
3. Synthesis of NIR probes	S16
4. Cell culture and confocal microscopy	S25
5. Cell viability studies	S26
6. In vivo imaging and biodistribution of breast, lung, and cervical tumor-bearing mice	S26
7. Ex vivo analysis of liver and tumor	S27
8. ¹ H NMR and ¹³ C NMR spectra of the probes	S28
9. References	S45

1. General information

Unless stated otherwise, all reactions were carried out under an atmosphere of argon using standard Schlenk techniques. All organic solvents were purchased from Fisher Scientific or Sigma Aldrich and purified with a solvent purification system (Innovative Technology). Sulfo-Cyanine5 carboxylic acid was purchased from Lumiprobe Corporation. Indocvanine green was purchased from Fisher Scientific, Dulbecco's Modified Eagle Medium (DMEM), RPMI-1640 Medium, and fetal bovine serum (FBS) were purchased from Sigma-Aldrich. LysoTracker Green and DAPI were purchased from Life Technologies. Sephadex LH-20 was purchased from GE Healthcare. ¹H NMR spectra were recorded on a Varian Mercury 500 MHz or Agilent Mercury 400 MHz spectrometer in chloroform-d or methanol-d. All signals were reported in ppm with chloroform signal at 7.26 ppm or methanol signals at 3.31, 4.87 ppm as a standard. Data for ¹H NMR were recorded as follows: chemical shift (δ , ppm), multiplicity (s = singlet, d = doublet, t = triplet, q = quartiplet, m = multiplet or unresolved, coupling constant(s) in Hz, integration). ¹³C NMR spectra were recorded on an Agilent Mercury 400 MHz spectrometer in chloroform-d. All signals are reported in ppm with the internal chloroform signal at 77.0 ppm as a standard. Column chromatography was performed either manually or on a Teledyne-Isco CombiFlash. The fluorescence emission spectra were obtained on a Hitachi fluorometer (F-7500 model). The UV-Vis spectroscopy study was performed on a Shimadzu UV-Vis spectrophotometer (UV-1800 model). Confocal microscopy imaging was performed using a Zeiss LSM 700 Confocal and images were analyzed using ImageJ (NIH). The whole body and ex vivo organ fluorescence imaging was performed on an IVIS Lumina System (Caliper Life Sciences). Luminescence measurements were performed on a Tecan InfiniTe F/M200 Pro microplate reader.

2. Supplemental Tables and Figures

2.1 Modified reaction conditions of Knoevenagel condensation.^a




 Table S1. Reaction optimization of Knoevenagel condensation reaction.

Entry	Solvent	Temp. (°C)	Time (h)	Product	Conversion
1	Toluene	120	24	P1, P2	<u> </u>
2 ^b	Toluene	120	24	P1, P2	c
3	EtOH	85	24	P1, P2	c
4	CH ₃ CN	85	1.5	P1	> 80%
5	CH ₃ CN	85	8	P2	> 90%

^{*a*}Reaction conditions: **1b** (0.03 mmol), **A1** (0.18 mmol), piperidine (60 μ L), and HOAc (36 μ L) in solvent (1 mL) with 4 Å molecular sieves. ^{*b*}Piperidine/TsOH as catalyst. ^{*c*}Not determined.

The condensation of a tetramethyl-BODIPY scaffold with an aromatic aldehyde was usually refluxed in dry toluene in the presence of piperidine and glacial acetic acid (classic Knoevenagel conditions).^[1-4] Any water formed during the reaction was removed azeotropically by heating in a Dean-Stark apparatus. However, these reactions usually require high temperature and long reaction time. Moreover, the conversions for such reactions were low.^[1-4] After screening, we found acetonitrile was the optimized solvent for such condensation reactions. **P1** was mainly formed after 1.5 h in refluxing CH₃CN (entry 4). However, **P2** could be mainly obtained after an extended reaction time (8 h, entry 5).

2.2 Photo-physical properties of NIR BODIPYs.

Probe	Solvent	$\lambda_{abs}, \max(nm)^{a}$	$\lambda_{em}, \max(nm)^{b}$	$\Phi_{ m FL}{}^{c}$	pKa
2 b	DMSO	705	746	d	
3 b	DMSO	660	730	<u></u> d	
5a	H_2O	645	660	0.09	
5b-1	H_2O	640	651	0.18^{e}	2.9
5b-2	H_2O	648	668	0.23 ^e	3.1
5c	H_2O	648	670	0.22^{e}	4.5
5d	H_2O	648	667	0.23^{f}	1.75
5e	H_2O	648	668	0.25 ^e	4.0

Table S2. Spectroscopic properties of 2b, 3b, and 5a-e.

^{*a*}The UV-Vis spectroscopy study was performed on a Shimadzu UV-Vis spectrophotometer (UV-1800 model). ^{*b*}The fluorescence emission spectra were obtained on a Hitachi fluorometer (F-7500 model). ^{*c*}The reported quantum yield was calculated according to the following equation: $\Phi_{sample} = \Phi_{standard}$ (A_{standard} / A_{sample}) (F_{sample} / F_{standard}) (n_{sample} / n_{standard})², where " Φ " is the quantum yield, "A" is the absorbance at the excitation frequency, "F" is the integrated area under the emission curve, and "n" is the refractive index of the solvent used. Sulfo-Cyanine5 carboxylic acid (sulfo-Cy5) ($\Phi_{fl} = 0.2$) in water was used as the fluorescence standard. ^{*d*}Not determined. ^{*e*}In 0.01 M aqueous HCl. ^{*f*}In 0.1 M aqueous HCl.

2.3 Supplemental Figures.




Figure S1. Water-soluble PEGylated NIR BODIPYs activate in response to a decrease in pH by photo-induced electron transfer (PeT) mechanism. Electron flow is involved in a PeT process from the aniline group to the excited BODIPY core as shown in the frontier molecular orbital diagram.




Figure S2. (A) Fluorescence emission spectra of **2b** in DMSO (10 μ M) and MeOH (10 μ M). Each sample was excited at 705 nm, and emission spectra were collected from 715 to 900 nm. (B) Fluorescence emission spectra of **3b** in DMSO (10 μ M) and MeOH (10 μ M). Each sample was excited at 660 nm, and emission spectra were collected from 680 to 900 nm.




Figure S3. (A) Fluorescence emission spectra of 4b-1 in DMSO (10 μ M) and MeOH (10 μ M). 4b-1 can only turn on in acidic DMSO or MeOH. Each sample was excited at 640 nm, and emission spectra were collected from 650 to 800 nm. (B) Fluorescence emission spectra of 5b-1 in DMSO (10 μ M) and MeOH (10 μ M). 5b-1 can only turn on in acidic DMSO or MeOH. Each sample was excited at 640 nm, and emission spectra were collected from 650 to 800 nm.




Figure S4. To help understand the origin of the increased T/L ratio, the tumor and liver were homogenized and **5c** was extracted into methanol to completely isolate **5c**. Probe **5c** is off in neutral methanol, but will immediately turn on in acidic methanol. Thus, we were able to calibrate and quantify the total uptake of **5c** in the tissues after adding a small amount of trifluoroacetic acid (TFA) to the methanol extracts. (A) Fluorescence emission spectra of **4c** in DMSO (10 μ M) and MeOH (10 μ M). **4c** can only turn on in acidic DMSO or MeOH. Each sample was excited at 640 nm, and emission spectra were collected from 650 to 800 nm. (B) Fluorescence emission spectra of **5c** in DMSO (10 μ M) and MeOH (10 μ M). **5c** can only turn on in acidic DMSO or MeOH. Each sample was excited at 640 nm, and emission spectra were collected from 650 to 800 nm.




Figure S5. Confocal fluorescence microscope images (20X) of the **5** series of probes in Hela cells. Cells (10,000 cells/well) were incubated with **5** (5.0 μ M) for 30 min at 37 °C, and the media was replaced with fresh media containing lysotracker green (0.5 μ M) and incubated for 20 min. Then the cells were fixed with 4% paraformaldehyde. Cell nucleus was stained with DAPI (0.3 μ M). The NIR probe is red; lysosomes are green; and the cell nuclei are blue. Colocalization is seen as yellow. **5a** did not exhibit bright fluorescence due to low quantum yield and uptake in short time. Scale bar = 20 μ m.




Figure S6. Confocal fluorescence microscope images (20X) of the **5** series of probes in Hela cells. Cells (10,000 cells/well) were incubated with **5** (5.0 μ M) for 4 h at 37 °C, and the media was replaced with fresh media containing lysotracker green (0.5 μ M) and incubated for 30 min. Then the cells were fixed with 4% paraformaldehyde. Cell nucleus was stained with DAPI (0.3 μ M). The NIR probe is red; lysosomes are green; and the cell nuclei are blue. Co-localization is seen as yellow. Scale bar = 20 μ m.




Figure S7. Confocal fluorescence microscope images (20X) of the **5** series of probes in Huh7 cells. Cells (10,000 cells/well) were incubated with **5** (5.0 μ M) for 4 h at 37 °C, and the media was replaced with fresh media containing lysotracker green (0.5 μ M) and incubated for 30 min. Then the cells were fixed with 4% paraformaldehyde. Cell nucleus was stained with DAPI (0.3 μ M). The NIR probe is red; lysosomes are green; and the cell nuclei are blue. Co-localization is seen as yellow. Scale bar = 20 μ m.




Figure S8. Confocal fluorescence microscope images (20X) of the **5** series of probes in HCC4017 cells. Cells (10,000 cells/well) were incubated with **5** (5.0 μ M) for 4 h at 37 °C, and the media was replaced with fresh media containing lysotracker green (0.5 μ M) and incubated for 30 min. Then the cells were fixed with 4% paraformaldehyde. Cell nucleus was stained with DAPI (0.3 μ M). The NIR probe is red; lysosomes are green; and the cell nuclei are blue. Colocalization is seen as yellow. Scale bar = 20 μ m.




Figure S9. CellTiter-Glo luminescent cell viability assay in Hela cells. Cell viability was measured after addition of 5a-e with different concentrations and 24 hours incubation compared to untreated cells (n = 3).




Figure S10. Probe **5c** for MDA-MB-231 tumor imaging *in vivo* and *ex vivo*. (A) Nude mice bearing two MDA-MB-231 tumors were injected with a dosage of 0.5 mg/kg **5c** (10 μ M, 200 μ L in PBS) via intratumoral injection. NIR fluorescence images at selected time-points were captured. (B) At 6 days post-injection, mice were sacrificed and organs were collected and imaged using an IVIS Lumina imaging system.

Color Scale Min = 9.36e7 Max = 1.02e




Figure S11. Representative *ex vivo* fluorescence images of harvested tumors and organs of MDA-MB-231 tumor-bearing mice sacrificed at 24 h post-injection. Nude mice bearing two MDA-MB-231 tumors were intravenously administered with probe **5c** (10 μ M, 200 μ L in PBS) at a dose of 0.5 mg/kg via the tail vein and, 24 h later, organs were collected for NIR imaging using an IVIS Lumina imaging system.




Figure S12. Representative *ex vivo* fluorescence images of collected tumors and organs of MDA-MB-231 tumor-bearing mice sacrificed at 15 min post-injection. (A) MDA-MB-231 tumor-bearing mice were intravenously injected with ICG (10 μ M, 200 μ L in PBS) via the tail vein and, 15 min later, organs were collected for NIR imaging. (B) MDA-MB-231 tumor-bearing mice were intravenously injected with sulfo-Cy5 (10 μ M, 200 μ L in PBS) via the tail vein and, 15 min later, organs were collected for NIR imaging.




Figure S13. Time-dependent *in vivo* fluorescence images of subcutaneous HCC4017 tumorbearing mice after intravenous injection of 0.5 mg/kg (10 μ M, 200 μ L) pH-activatable probe **5c** *via* the tail vein.




Figure S14. Probe **5c** for Hela tumor imaging *in vivo* and *ex vivo*. (A) Time-dependent *in vivo* fluorescence images of subcutaneous Hela tumor-bearing mice after intravenous injection of 0.5 mg/kg (10 μ M, 200 μ L) pH-activatable probe **5c** *via* the tail vein. (B) NIR fluorescence imaging 8 h post i.v. administration of **5c** without intensity scale adjusted. (C) At 8 h post-injection, mice were sacrificed and organs were collected and imaged using an IVIS Lumina imaging system.





Figure S15. Illustration of microenvironment in tumor and liver. (A) The tumor and liver were harvested from a HCC4017 tumor-bearing mouse. *Ex vivo* imaging of collected tumor and liver was performed 10 min after direct injection of **5c** (1 μ M, 100 μ L). (B) *Ex vivo* image of collected tumor and liver was performed after injection of **5a** (1 μ M, 100 μ L) at 10 min post-injection.

3. Synthesis of NIR probes


3.1 General procedure for the synthesis of BODIPYs **1a-e**.^[5, 6]




2,4-dimethylpyrrole (1.0 mL, 10.0 mmol) and the appropriate *N*,*N*-dialkylaminobenzaldehyde or benzaldehyde (5.0 mmol) were dissolved in 600 mL of anhydrous dichloromethane (DCM) containing a catalytic amount of trifluoroacetic acid (TFA). The resulting reddish solution was stirred overnight at ambient temperature under an Ar atmosphere. Tetrachloro-1,4-benzoquinone (*p*-chloranil) (1.23 g, 5.0 mmol) was added and the mixture was stirred for 1 h. Then the DCM was removed under reduced pressure. The residue thus obtained was dissolved in 300 mL of dry toluene containing *N*,*N*-diisopropylethylamine (DIPEA) (6 mL), and the resulting solution was stirred at ambient temperature. BF₃·OEt₂ (6 mL) was then slowly added, and stirring was continued for 2 h. The reaction mixture was washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by flash column chromatography over silica gel using DCM/hexanes as the eluent. Then the collected product was recrystallized in CH_2Cl_2 /hexanes (10/90), affording **1a-e** as brown-red solid.




^{1a} Yield = 16%; ¹H NMR (400 MHz, CDCl₃): δ 7.51-7.48 (m, 3H), 7.29-7.26 (m, 2H), 5.98 (s, 2H), 2.56 (s, 6H), 1.37 (s, 6H).




^{1b} Yield = 45%; ¹H NMR (500 MHz, CDCl₃): δ 7.05 (d, J = 8.5 Hz, 2H), 6.78 (d, J = 8.0 Hz, 2H), 5.97 (s, 2H), 3.02 (s, 6H), 2.55 (s, 6H), 1.48 (s, 6H).



^{1c} Yield = 27%; ¹H NMR (400 MHz, CDCl₃): δ 7.01 (d, J = 8.4 Hz, 2H), 6.73 (d, J = 8.4 Hz, 2H), 5.95 (s, 2H), 3.40 (q, J = 7.2 Hz, 4H), 2.54 (s, 6H), 1.51 (s, 6H), 1.19 (t, J = 7.2 Hz, 6H).




^{1d} Yield = 32%; ¹H NMR (400 MHz, CDCl₃): δ 7.03 (d, J = 8.8 Hz, 2H), 6.61 (d, J = 8.8 Hz, 2H), 5.96 (s, 2H), 3.33 (t, J = 6.4 Hz, 4H), 2.55 (s, 6H), 2.07-2.04 (m, 4H), 1.51 (s, 6H). ¹³C NMR (100 MHz, CDCl₃): δ 154.55, 148.10, 143.56, 143.25, 132.27, 128.77, 121.14, 120.74, 111.79, 47.53, 25.43, 14.79, 14.54. LRMS-ESI (*m/z*): Exact mass calcd for C₂₃H₂₇BF₂N₃⁺ [M+H]⁺: 394.2; Found: 394.2.



1e Yield = 30%; ¹H NMR (400 MHz, CDCl₃): δ 7.08 (d, J = 8.8 Hz, 2H), 7.00 (d, J = 8.0 Hz, 2H), 5.96 (s, 2H), 3.23 (t, J = 5.3 Hz, 4H), 2.54 (s, 6H), 1.74-1.73 (m, 4H), 1.64-1.58 (m, 2H), 1.46 (s, 6H).


3.2 Synthesis of NIR BODIPY **2b**.



BODIPY **1b** (184 mg, 0.5 mmol) and 1,3-dimethyl-1*H*-indole-2-carbaldehyde (520 mg, 3.0 mmol) were refluxed in a mixture of dry acetonitrile (20 mL), piperidine (1.0 mL), glacial acetic acid (0.6 mL), and 4 Å molecular sieves (~50 pellets) under an Ar atmosphere. The reaction mixture was stirred at 85 °C for 8 h. Then the solvent was removed under reduced pressure. The crude product was purified by flash column chromatography over silica gel using ethyl acetate/hexanes as the eluent. The collected product was then recrystallized in CH₂Cl₂/hexanes (10/90), affording **2b** as gold-brown solid.

Yield = 65%; ¹H NMR (400 MHz, CDCl₃): δ 7.68 (d, *J* = 16.8 Hz, 2H), 7.60 (d, *J* = 8.0 Hz, 2H), 7.36 (d, *J* = 16.4 Hz, 2H), 7.30-7.24 (m, 4H), 7.14-7.10 (m, 4H), 6.81 (d, *J* = 8.4 Hz, 2H), 6.68 (s, 2H), 3.88 (s, 6H), 3.04 (s, 6H), 2.56 (s, 6H), 1.59 (s, 6H). ¹³C NMR (100 MHz, CD₂Cl₂): δ 152.2, 151.4, 143.0, 140.3, 139.2, 134.9, 134.5, 129.8, 129.1, 124.0, 123.8, 122.5, 121.3, 119.8, 119.7, 117.3, 114.6, 112.8, 109.7, 40.7, 31.4, 15.3, 10.8. LRMS-ESI (*m/z*): Exact mass calcd for C₄₃H₄₃BF₂N₅⁺ [M+H]⁺: 678.4; Found: 678.2.


3.3 Synthesis of NIR BODIPY **3b**.



BODIPY **1b** (184 mg, 0.5 mmol) and the Fisher aldehyde (131 mg, 1.3 mmol) were refluxed in a mixture of dry acetonitrile (20 mL), piperidine (1.0 mL), glacial acetic acid (0.6 mL), and 4 Å molecular sieves (~50 pellets) under an Ar atmosphere. The reaction mixture was stirred at 85 °C for 2 h. Then the solvent was removed under reduced pressure. The crude product was purified by flash column chromatography over silica gel using ethyl acetate/hexanes as the eluent. The collected product was then recrystallized in $CH_2Cl_2/Hexanes$ (10/90), affording **3b** as brown-green solid.

Yield = 50%; ¹H NMR (500 MHz, CDCl₃): δ 7.55 (t, *J* = 13.5 Hz, 1H), 7.20 (t, *J* = 7.5 Hz, 1H), 7.16 (d, *J* = 7.0 Hz, 1H), 7.10-7.09 (m, 2H), 6.91-6.78 (m, 4H), 6.69 (d, *J* = 7.5 Hz, 1H), 6.49 (s, 1H), 5.91 (s, 1H), 5.66 (d, *J* = 11.5 Hz, 1H), 3.18 (s, 3H), 3.02 (s, 6H), 2.55 (s, 3H), 1.60 (s, 6H), 1.52 (s, 3H), 1.46 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 160.6, 155.4, 150.4, 149.9, 144.6, 143.2, 139.1, 138.7, 138.1, 135.2, 134.2, 131.4, 129.3, 127.8, 123.0, 121.6, 120.4, 119.2, 117.4, 114.2, 112.2, 106.6, 98.4, 46.1, 40.4, 30.9, 29.2, 28.7, 15.0, 14.4. LRMS-ESI (*m/z*): Exact mass calcd for C₃₄H₃₈BF₂N₄⁺ [M+H]⁺: 551.3; Found: 551.2.


3.4 General experimental procedure for synthesis of **5a-e**.




BODIPY 1 (0.5 mmol) and the appropriate propargyl benzaldehyde A3 (3.0 mmol) were refluxed in a mixture of dry acetonitrile (20 mL), piperidine (1.0 mL), glacial acetic acid (0.6 mL), and 4 Å molecular sieves (~50 pellets) under an Ar atmosphere. The reaction mixture was

stirred at 85 °C for 8 h. Then the solvent was removed under reduced pressure. The crude product was first purified by flash column chromatography over silica gel using ethyl acetate/hexanes as the eluent to remove the excess A3. Subsequently, the eluent was changed to DCM/hexanes to obtain the desired product. The collected product was then recrystallized in CH_2Cl_2 /hexanes (10/90), yielding 4 as gold-brown or dark-blue solid.

NIR BODIPY 4 (0.04 mmol), methoxy-poly(ethylene glycol)-azide (PEG-N₃, average M_n = 2000, 192 mg, 0.096 mmol), CuSO₄ (1.3 mg, 0.008 mmol), and sodium ascorbate (VcNa, 15.8 mg, 0.08 mmol) were added to a 10 mL schlenk flask. The vessel was evacuated and back-filled with Ar. Then the flask was cooled to 0 °C for 20 minutes and 4 mL THF (degassed) was added via a syringe, followed by 1 mL DI water (degassed). The reaction mixture was slowly warmed to room temperature and stirred overnight. After evaporation of THF, the residue was dialyzed in DI water for 6 h and lyophilized to obtain a blue powder. The collected product was then purified by column chromatography through a Sephadex LH-20 resin using MeOH as the eluent, affording **5a-e** as blue solid.




Yield = 49%; ¹H NMR (400 MHz, CDCl₃): δ 7.65-7.59 (m, 6H), 7.51-7.49 (m, 3H), 7.34-7.32 (m, 2H), 7.21 (d, *J* = 16.0 Hz, 2H), 7.01 (d, *J* = 8.8 Hz, 2H), 6.62 (s, 2H), 4.74 (d, *J* = 2.4 Hz, 4H), 2.56 (t, *J* = 2.4 Hz, 2H), 1.44 (s, 6H). ¹³C NMR (100 MHz, CDCl₃): δ 158.2, 152.6, 141.9, 138.4, 135.5, 135.2, 133.2, 130.4, 129.03, 128.95, 128.9, 128.5, 117.7, 117.5, 115.2, 78.2, 75.8, 55.8, 14.6. LRMS-ESI (*m/z*): Exact mass calcd for C₃₉H₃₂BF₂N₂O₂⁺ [M+H]⁺: 609.3; Found: 609.4.




 $\overset{\circ}{\longrightarrow} \overset{\circ}{\longrightarrow} \overset{\circ$


Hz, 2H), 1.58 (s, 6H). ¹³C NMR (100 MHz, CDCl₃): δ 165.4, 151.6, 150.8, 143.0, 141.8, 141.4, 134.7, 134.3, 130.3, 129.0, 127.3, 121.82, 121.79, 118.0, 112.3, 77.7, 75.0, 52.5, 40.3, 15.0. LRMS-ESI (*m/z*): Exact mass calcd for C₄₃H₃₇BF₂N₃O₄⁺ [M+H]⁺: 708.3; Found: 708.2.




Yield = 61%; ¹H NMR (400 MHz, CDCl₃): δ 7.65-7.58 (m, 6H), 7.19 (d, *J* = 16.0 Hz, 2H), 7.10 (d, *J* = 8.0 Hz, 2H), 7.01 (d, *J* = 8.4 Hz, 4H), 6.79 (d, *J* = 8.4 Hz, 2H), 6.61 (s, 2H), 4.74 (d, *J* = 2.0 Hz, 4H), 3.03 (s, 6H), 2.55 (t, *J* = 2.4 Hz, 2H), 1.55 (s, 6H). ¹³C NMR (100 MHz, CDCl₃): δ 158.1, 152.1, 150.6, 142.1, 140.0, 134.9, 134.0, 130.5, 129.2, 128.9, 122.4, 117.9, 117.2, 115.2, 112.2, 78.3, 75.8, 55.8, 40.3, 14.9. LRMS-ESI (*m/z*): Exact mass calcd for C₄₁H₃₇BF₂N₃O₂⁺ [M+H]⁺: 652.3; Found: 652.2.




Yield = 60%; ¹H NMR (400 MHz, CDCl₃): δ 7.65-7.58 (m, 6H), 7.19 (d, *J* = 16.4 Hz, 2H), 7.06 (d, *J* = 8.4 Hz, 2H), 7.01 (d, *J* = 8.4 Hz, 4H), 6.75 (d, *J* = 8.8 Hz, 2H), 6.61 (s, 2H), 4.74 (d, *J* = 2.4 Hz, 4H), 3.41 (q, *J* = 7.2 Hz, 4H), 2.55 (t, *J* = 2.4 Hz, 2H), 1.58 (s, 6H), 1.21 (t, *J* = 7.2Hz, 6H). ¹³C NMR (100 MHz, CDCl₃): δ 158.0, 152.0, 148.1, 142.1, 140.3, 134.8, 134.0, 130.5, 129.3, 128.8, 121.4, 117.9, 117.2, 115.1, 111.9, 78.3, 75.8, 55.8, 44.3, 15.0, 12.4. LRMS-ESI (*m/z*): Exact mass calcd for C₄₃H₄₁BF₂N₃O₂⁺ [M+H]⁺: 680.3; Found: 680.2.




Yield = 86%; ¹H NMR (400 MHz, CDCl₃): δ 7.64-7.58 (m, 6H), 7.19 (d, *J* = 16.0 Hz, 2H), 7.11 (d, *J* = 8.0 Hz, 2H), 7.01 (d, *J* = 8.4 Hz, 4H), 6.73 (d, *J* = 5.6 Hz, 2H), 6.61 (s, 2H), 4.74 (d, *J* = 2.4 Hz, 4H), 3.38 (m, 4H), 2.55 (t, *J* = 2.0 Hz, 2H), 2.09 (m, 4H), 1.56 (s, 6H). ¹³C NMR (100 MHz, CDCl₃): δ 158.0, 152.0, 148.1, 142.2, 140.4, 134.8, 134.1, 130.5, 129.2, 128.8, 121.4, 118.0, 117.1, 115.1, 111.7, 78.3, 75.8, 55.8, 47.6, 25.4, 15.0. LRMS-ESI (*m/z*): Exact mass calcd for C₄₃H₃₉BF₂N₃O₂⁺ [M+H]⁺: 678.3; Found: 678.2.




Yield = 50%; ¹H NMR (400 MHz, CDCl₃): δ 7.64-7.58 (m, 6H), 7.19 (d, *J* = 16.0 Hz, 2H), 7.13 (d, *J* = 8.8 Hz, 2H), 7.03-7.00 (m, 6H), 6.61 (s, 2H), 4.74 (d, *J* = 2.4 Hz, 4H), 3.24 (t, *J* = 5.6 Hz, 4H), 2.55 (t, *J* = 2.4 Hz, 2H), 1.78-1.72 (m, 4H), 1.65-1.61 (m, 2H), 1.53 (s, 6H). ¹³C NMR (100 MHz, CDCl₃): δ 158.1, 152.4, 152.2, 142.1, 139.4, 135.1, 133.8, 130.5, 129.1, 128.9, 125.0, 117.9, 117.3, 116.2, 115.2, 78.3, 75.8, 55.8, 50.1, 25.6, 24.2, 14.9. LRMS-ESI (*m/z*): Exact mass calcd for C₄₄H₄₁BF₂N₃O₂⁺ [M+H]⁺: 692.3; Found: 692.2.




^{$\dot{P}EG_{2000}$} 2000^{GEP} Yield = 92%; ¹H NMR (400 MHz, CD₃OD): δ 8.19 (s, 2H), 7.64-7.55 (m, 9H), 7.43-7.39 (m, 4H), 7.12 (d, J = 8.4 Hz, 4H), 6.83 (s, 2H), 5.27 (s, 4H), 4.62 (t, J = 4.8 Hz, 4H), 3.90 (t, J = 4.8 Hz, 4H), 3.64-3.57 (m, 344H), 3.35 (s, 6H), 1.48 (s, 6H).




 $\stackrel{i}{\mathsf{PEG}_{2000}}$ $\stackrel{i}{\mathsf{PEG}_{2000}}$ Yield = 93%; ¹H NMR (400 MHz, CD₃OD): δ 8.22 (s, 2H), 8.09 (d, J = 8.4 Hz, 4H), 7.82-7.75 (m, 6H), 7.50 (d, J = 16.4 Hz, 2H), 7.15 (d, J = 8.8 Hz, 2H), 6.93 (d, J = 8.8 Hz, 2H), 6.90 (s, 2H), 5.48 (s, 4H), 4.64 (t, J = 4.8 Hz, 4H), 3.92 (t, J = 4.8 Hz, 4H), 3.63-3.57 (m, 344H), 3.35 (s, 6H), 3.04 (s, 6H), 1.62 (s, 6H).




^{$\dot{P}EG_{2000}$} 2000^{GEP} Yield = 84%; ¹H NMR (400 MHz, CD₃OD): δ 8.19 (s, 2H), 7.63-7.56 (m, 6H), 7.38 (d, J = 16.4 Hz, 2H), 7.14-7.10 (m, 6H), 6.91 (d, J = 8.8 Hz, 2H), 6.80 (s, 2H), 5.26 (s, 4H), 4.61 (t, J = 4.8 Hz, 4H), 3.90 (t, J = 4.8 Hz, 4H), 3.63-3.57 (m, 344H), 3.35 (s, 6H), 3.04 (s, 6H), 1.59 (s, 6H).



^{$\dot{P}EG_{2000}$} 2000^{GEP} Yield = 91%; ¹H NMR (400 MHz, CD₃OD): δ 8.19 (s, 2H), 7.62 (d, J = 8.4 Hz, 4H), 7.57 (d, J = 17.6 Hz, 2H), 7.38 (d, J = 16.0 Hz, 2H), 7.13-7.10 (m, 6H), 6.88 (d, J = 8.8 Hz, 2H), 6.80 (s, 2H), 5.27 (s, 4H), 4.62 (t, J = 4.8 Hz, 4H), 3.90 (t, J = 4.8 Hz, 4H), 3.63-3.57 (m, 348H), 3.35 (s, 6H), 1.63 (s, 6H), 1.21 (t, J = 7.2 Hz, 6H).



^{$\dot{P}EG_{2000}$} Yield = 86%; ¹H NMR (400 MHz, CD₃OD): δ 8.18 (s, 2H), 7.61 (d, J = 8.8 Hz, 4H), 7.56 (d, J = 16.4 Hz, 2H), 7.38 (d, J = 16.0 Hz, 2H), 7.12-7.09 (m, 6H), 6.80 (s, 2H), 6.73 (d, J = 8.4 Hz, 2H), 5.26 (s, 4H), 4.61 (t, J = 4.8 Hz, 4H), 3.89 (t, J = 4.8 Hz, 4H), 3.64-3.56 (m, 344H), 3.35-3.33 (m, 10H), 2.07 (m, 4H), 1.60 (s, 6H).



^{$\dot{P}EG_{2000}$} 2000^{GEP'} Yield = 85%; ¹H NMR (400 MHz, CD₃OD): δ 8.18 (s, 2H), 7.62 (d, J = 8.8 Hz, 4H), 7.56 (d, J = 16.0 Hz, 2H), 7.39 (d, J = 16.4 Hz, 2H), 7.17-7.10 (m, 8H), 6.81 (s, 2H), 5.27 (s, 4H), 4.61 (t, J = 4.8 Hz, 4H), 3.90 (t, J = 4.8 Hz, 4H), 3.63-3.56 (m, 344H), 3.35 (s, 6H), 3.30 (m, 4H), 1.75-1.73 (m, 4H), 1.65 (m, 2H), 1.58 (s, 6H).

4. Cell culture and confocal microscopy

All cell lines were cultured in high glucose Dulbecco's Modified Eagle's Medium or RPMI-1640 medium containing 5% fetal bovine serum (FBS). Cells were maintained at 37 °C under a humidified atmosphere with 5% CO₂. (DMEM for Hela, Huh7, and A549 cell lines. RPMI for MDA-MB-231, SKOV3, and HCC4017 cell lines.) Prior to confocal imaging studies, cells were seeded at a density of 10,000 cells per well in 8chambered cover glass slides (Nunc) in 300 μ L of media and allowed to attach for 24 hours. On the following day, the media was removed and replaced with fresh DMEM or RPMI (300 μ L). The probe of interest (**5a-e**) (5 μ M) was added and the cells were incubated for 30 min or 4 h. Then the cells were washed twice with phosphate buffered saline (PBS) and incubated with the LysoTracker Green DND-26 (0.5 μ M, 200 μ L) for 30 min. The cells were fixed by 4% PFA (200 μ L) and stained with DAPI (0.3 μ M, 200 μ L) for 10 min. After labeling, cells were washed twice with PBS and incubated with fresh PBS for fluorescence imaging. Confocal microscopy imaging was performed using a Zeiss LSM 700 Confocal. All imaging settings were held constant across all experiments imaging different probes. The use of identical settings allowed for proper comparison of different dyes. Images were analyzed using ImageJ (NIH).

5. Cell viability studies

HeLa cells were seeded in white opaque flat-bottom 96-well plates at a cell density of 10,000 cells per well in 100 μ L growth medium. After 24 h to allow cell adhesion, the medium was exchanged for 180 μ L fresh growth medium. Probes **5a-e** were serially diluted in PBS. Probe dilutions (100 μ L) were added to the cells via multichannel pipette for final micelle concentrations of 2.3 to 154.7 μ M. The cells were then incubated for 24 hours. After this time, cell viability was evaluated by the CellTiter-Glo assay and normalized to a PBS control, n = 3.


6. *In vivo* imaging and biodistribution of breast, lung, and cervical tumorbearing mice


Female athymic nude Foxn1^{nu} mice were purchased from Harlan Laboratories. All experiments were approved by the Institutional Animal Care and Use Committees of The University of Texas Southwestern Medical Center and were consistent with local, state and federal regulations as applicable. MDA-MB-231, HCC4017, or Hela tumor cells (5×10^6) in 100 μ L HBSS/Matrigel (v/v, 50/50) were injected subcutaneously into each flank of 6 weeks old nude mice. After three (for breast and cervical tumor) or five (for lung tumor) weeks, when the tumors reached adequate size, probe **5c** (10 μ M) in 200 μ L PBS was injected intravenously through the tail vein (0.5 mg/kg dose i.v.). In the control groups, the "always on" probe **5a** or sulfo-Cy5 or ICG (10 μ M, 200 μ L) was administrated i.v. For the intratumoral injection, 200 μ L of **5c** in PBS (10 μ M) was directly injected into the tumor. Mice were anesthetized with 2.5 % isofluorane in oxygen at selected time points and the whole body NIR fluorescence images (the Cy5.5 filter was used) were captured using an IVIS Lumina imaging system (Caliper Life Sciences). At the end point (6 h, 8 h, or 24 h), mice were euthanized and their livers, tumors, lungs, hearts, kidneys, spleens, and muscle were collected. *Ex vivo* fluorescence imaging of these


organs was immediately performed on the IVIS Lumina. The fluorescent signal of organs was normalized to the fluorescent signal in the muscle within a representative region of interest (ROI).


7. Ex vivo analysis of liver and tumor


Female athymic nude Foxn1^{nu} mice (n = 3) bearing subcutaneous MDA-MB-231 tumors were intravenously injected with pH-activatable probe **5c** at a dose of 0.5 mg/kg (10 µM, 200 µL in PBS) *via* the tail vein. The mice were sacrificed at 8 hours post-injection. Liver and tumor were immediately collected and frozen in OCT (Tissue-Tek, Sakura Finetek, Torrance, CA) at -20 °C for 20 min. Then the frozen tissues were cut into 10 µm sections using Leica CM3050 S cryostat. The sections were fixed in cold acetone (-20 °C) for 10 min, washed with PBS for 5 min (3×), and mounted with medium containing DAPI (Vector Laboratories Inc., CA, USA). Fluorescence images were captured on a Zeiss LSM 700 Confocal and analyzed using ImageJ (NIH).















































S44

9. References

(1) Galangau, O.; Dumas-Verdes, C.; Méallet-Renault, R.; Clavier, G. Org. Biomol. Chem. 2010, 8, 4546.

(2) He, H.; Lo, P.-C.; Yeung, S.-L.; Fong, W.-P.; Ng, D. K. P. Chem. Commun. 2011, 47, 4748.

(3) Zheng, Q.; Xu, G.; Prasad, P. N. Chem. Eur. J. 2008, 14, 5812.

(4) Bura, T.; Retailleau, P.; Ulrich, G.; Ziessel, R. J. Org. Chem. 2011, 76, 1109.

(5) Urano, Y.; Asanuma, D.; Hama, Y.; Koyama, Y.; Barrett, T.; Kamiya, M.; Nagano, T.; Watanabe, T.; Hasegawa, A.; Choyke, P. L.; Kobayashi, H. *Nat. Med.* **2009**, *15*, 104.

(6) Shie, J.-J.; Liu, Y.-C.; Lee, Y.-M.; Lim, C.; Fang, J.-M.; Wong, C.-H. J. Am. Chem. Soc. **2014**, *136*, 9953.